Capricor Therapeutics, Inc.（CAPR）の財務CAPRCapricor Therapeutics, Inc.

Evaluating the bottom line, Capricor Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -73.70%, provide a clear picture of how effectively CAPR converts its operational activities into shareholder value.

In the context of the broader market, CAPR competes directly with industry leaders such as TKNO and RLMD. With a market capitalization of $344.76M, it holds a significant position in the sector. When comparing efficiency, CAPR's gross margin of N/A stands against TKNO's 37.73% and RLMD's N/A. Such benchmarking helps identify whether Capricor Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Capricor has reported a gross margin of 100% for Q4 2024, but has not generated revenue since then, leading to substantial net losses, including a projected net income loss of -$40,733,654 for Q2 2026.